Showing results (11-20 of 73) with videos related to
Sort By:
Pageof 8
Nature|November 28, 2014
MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancerThomas Powles, Joseph Paul Eder, Gregg D Fine, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 31, 2019
Safety, Clinical Activity, and Biological Correlates of Response in Patients with Metastatic Melanoma: Results from a Phase I Trial of AtezolizumabOmid Hamid, Luciana Molinero, Christopher R Bolen, et al.Science Translational Medicine|March 13, 2020
Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapyMaud Mayoux, Andreas Roller, Vesna Pulko, et al.Nature Communications|August 31, 2016
Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinomaJeffrey J Wallin, Johanna C Bendell, Roel Funke, et al.Molecular Cancer Therapeutics|March 29, 2013
HGF as a circulating biomarker of onartuzumab treatment in patients with advanced solid tumorsElicia Penuel, Congfen Li, Vaishali Parab, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|September 11, 2012
Pharmacokinetic and pharmacodynamic analysis of circulating biomarkers of anti-NRP1, a novel antiangiogenesis agent, in two phase I trials in patients with advanced solid tumorsYan Xin, Jessica Li, Jenny Wu, et al.Immunity|July 30, 2013
Oncology meets immunology: the cancer-immunity cycleDaniel S Chen, Ira MellmanNature|January 20, 2017
Elements of cancer immunity and the cancer-immune set pointDaniel S Chen, Ira MellmanCancer Journal (Sudbury, Mass.)|August 18, 2018
Combinations of Bevacizumab With Cancer ImmunotherapyDaniel S Chen, Herbert HurwitzPageof 8